版本:
中国

BRIEF-Karyopharm reports Q4 loss of $0.65 per share

March 16 Karyopharm Therapeutics Inc

* Karyopharm reports fourth quarter and full year 2016 financial results and provides Selinexor clinical update

* For quarter, research and development expense was $20.7 million compared to $24.1 million for quarter ended December 31, 2015

* Net loss $0.65 per share for quarter ended December 31, 2016

* Expects operating cash burn for year ending December 31, 2017 to be in range of $85 to 90 million

* Says expects to commence Boston study in early 2017

* Expects that existing cash and cash equivalents will fund its research and development programs and operations until end of 2018

* SDD ARM of Stomp study expected to enroll about 44 patients and Co expects to report top-line data in late 2017 or early 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐